|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products
Datamonitor, Aug 2007, Pages: 233
Introduction
The diabetes epidemic has contributed in the growth of the antidiabetics market the past few years. Since the prevalence of diabetes continues to increase, the market will further expand. While early therapy is dominated by generically available agents, and the later stages by insulin, the number of unmet needs in the diabetes treatment, warrants that novel agents will have a place in the market.
Scope
Country specific event-driven sales forecasts for the period 2007-16 for the US, Japan, France, Germany, Italy, Spain and the UK. Patient potential and prescribing trends overview of the antidiabetics market based on historical sales data and future key events. Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and class switching. Case studies presenting safety issues and the role that novel agents are likely to play in the balance of issues and opportunities in the market
Highlights
Insulin class dominates the market with a 40.9% share of its overall seven major market sales and the US market accounts for 66% of the value of the seven major markets with 13% CAGR 200306. Although insulin, sulfonylureas and biguanides remain the highest selling drug classes (number of units sold) in the antidiabetics market a strong need for new drugs with fewer side effects and better tolerability have created a potential niche for companies to compete for. Patients with Type 2 diabetes who are poorly controlled with metformin and/or sulfonylureas are subjects to second-line therapy with TZDs. For a number of years this class was in dispute due to its safety concerns.
Reasons to Purchase
Quantify future size and scope of the diabetes market and potential for new products Analyze options to expand commercial potential through pursuit of new indications Formulate successful launch strategies in a highly competitive market
Customers who bought this item also bought
Forecast Insight: Antidiabetics - Switching to New Molecule Antidiabetics Drives Market Growth
Commercial Insight: Antidiabetics - DPP-IV Inhibitors Poised to Sweep the Market
Pipeline Insight: Non-Insulin Antidiabetics – Incretin Mimetics – Leaders in a Diverse Pipeline
Pipeline Insight: Insulin Antidiabetics - Return to Injections - Alternative Delivery Methods Fall by the Wayside
Pipeline Insight: Non-Insulin Antidiabetics - Type 2 Diabetes Unlikely To Develop Into a Switch Market
Antidiabetics Market Forecast
The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market
Commercial Insight: Antidiabetics - Billion Dollar Drugs, Pipeline Dreams?
Diabetes Market Forecast to 2013
Commercial Insight: Antidiabetics in Australia - Reimbursement Status Shapes Novel Classes
Type 2 Diabetes Market Dynamics: Impact of Januvia and Other DPP-IV Inhibitors
The Diabetes Market Outlook to 2011
|
|
|
|
